Albuminuria‐lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross‐over clinical study
Annemarie B. van der Aart‐van der Beek(University of Groningen), Hiddo J.L. Heerspink(University Medical Center Groningen), Niels Jongs(University Medical Center Groningen), Ellen M. Apperloo(Dialyse Centrum Groningen), Klaas Hoogenberg(Martini Ziekenhuis), C. David Sjöström(University Medical Center Groningen), Dennis B. Rouw(Martini Ziekenhuis), L. E. B. Johansson(Swedish Institute of Space Physics), Daniël H. van Raalte(Amsterdam University Medical Centers), Iris Friedli(Antaros Medical (Sweden))
Cited by 28
Related Papers
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
|New England Journal of Medicine|2007|4.6k
Bariatric Surgery and Long-term Cardiovascular Events
|JAMA|2012|1.6k